PF-3845 is an inhibitor of fatty acid amide hydrolase (FAAH). PF-3845 shows anti-allodynic effects in mice stimulated with LPS. It generates this effect without displaying any cannabinolic effects, making it a target for inflammatory pain management. When PF-3845 is used in tandem with the monoacyglycerol lipase (MAGL) inhibitor JZL184, it lessens withdrawal effects from opioid-dependent mice and produces anti-nociceptive effects without cannabimimetic side effects. Studies of PF-3845 treatment for traumatic brain injury in mice showed that PF-3845 lessened impairments found in control mice.